Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 522

1.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Feb 14. doi: 10.1007/s10637-018-0569-x. [Epub ahead of print]

PMID:
29442210
2.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
3.

One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy.

Lems WF, Baak MM, van Tuyl LH, Lodder MC, Dijkmans BA, Boers M.

RMD Open. 2016 Sep 12;2(2):e000313. doi: 10.1136/rmdopen-2016-000313. eCollection 2016.

4.

Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures: Results of a Prospective Observational Cohort Study.

van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2016 Apr;43(4):758-64. doi: 10.3899/jrheum.150857. Epub 2016 Feb 15.

PMID:
26879348
5.

Changing phenotype of diffuse idiopathic skeletal hyperostosis over time: comment on the article by Saleem and Hawass.

Lemmers SA, Dijkmans BA, Janssen M.

Arthritis Rheumatol. 2015 Jun;67(6):1684-5. doi: 10.1002/art.39066. No abstract available.

6.

Objective evaluation of physical functioning after tumor necrosis factor inhibitory therapy in patients with ankylosing spondylitis: a selection of 3 feasible performance-based tests.

van Weely SF, Dekker J, Steultjens MP, van Denderen JC, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE.

J Rheumatol. 2015 Apr;42(4):623-9. doi: 10.3899/jrheum.140337. Epub 2015 Jan 15.

PMID:
25593234
7.

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.

Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, Tak PP, Posthumus MD, Wijmenga C, Huizinga T, van der Helm-van Mil AH, Stoeken-Rijsbergen G, Rodriguez-Rodriguez L, Balsa A, González-Álvaro I, González-Gay MÁ, Gómez-Vaquero C, Franke B; LifeLines Cohort Study, Vermeulen S, van der Horst-Bruinsma Ie, Dijkmans BA, Wolbink GJ, Ophoff RA, Maehlen MT, van Riel P, Merriman M, Klareskog L, Lie BA, Merriman T, Crusius JB, Brouwer E, Martin J, de Vries N, Toes R, Padyukov L, Koeleman BP.

Ann Rheum Dis. 2015 Mar;74(3):e15. doi: 10.1136/annrheumdis-2013-204591. Epub 2014 Feb 14.

PMID:
24532677
8.

Imported Armillifer pentastomiasis: report of a symptomatic infection in The Netherlands and mini-review.

Tappe D, Dijkmans AC, Brienen EA, Dijkmans BA, Ruhe IM, Netten MC, van Lieshout L.

Travel Med Infect Dis. 2014 Mar-Apr;12(2):129-33. doi: 10.1016/j.tmaid.2013.10.011. Epub 2013 Oct 31. Review.

9.

Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients.

Raterman HG, Voskuyl AE, Simsek S, Schreurs MW, van Hoogstraten IM, Peters MJ, van Halm VP, Dijkmans BA, Lips P, Lems WF, Nurmohamed MT.

Eur J Endocrinol. 2013 Oct 21;169(6):751-7. doi: 10.1530/EJE-13-0394. Print 2013 Dec.

10.

Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.

van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G.

Scand J Rheumatol. 2014;43(1):9-16. doi: 10.3109/03009742.2013.797490. Epub 2013 Aug 30.

PMID:
23987246
11.

What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function.

van Weely SF, van Denderen JC, Steultjens MP, Nurmohamed MT, Dijkmans BA, Dekker J, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2013 Oct;52(10):1884-9. doi: 10.1093/rheumatology/ket240. Epub 2013 Jul 17.

PMID:
23864170
12.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G.

Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2.

13.

Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.

Dirven L, Klarenbeek NB, van den Broek M, van Groenendael JH, de Sonnaville PB, Kerstens PJ, Huizinga TW, Dijkmans BA, Lems WF, Allaart CF.

Clin Rheumatol. 2013 May;32(5):585-90. doi: 10.1007/s10067-012-2136-8. Epub 2012 Dec 9.

PMID:
23224330
14.

Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus.

Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IE.

Osteoporos Int. 2013 Jun;24(6):1827-33. doi: 10.1007/s00198-012-2157-9. Epub 2012 Oct 3.

PMID:
23052940
15.

Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept.

van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT.

Clin Rheumatol. 2012 Dec;31(12):1677-82. doi: 10.1007/s10067-012-2072-7. Epub 2012 Sep 1.

PMID:
22941219
16.

Results of a questionnaire on the treatment of patients with Behçet's syndrome: a trend for more intensive treatment.

Turkstra F, van Vugt RM, Dijkmans BA, Yazici Y, Yazici H.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S10-3. Epub 2012 Sep 25.

PMID:
22776270
17.

High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review.

van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE.

Clin Rheumatol. 2012 Nov;31(11):1529-35. doi: 10.1007/s10067-012-2018-0. Epub 2012 Jun 16. Review.

18.

HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab.

Raterman HG, Levels H, Voskuyl AE, Lems WF, Dijkmans BA, Nurmohamed MT.

Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/annrheumdis-2011-201228. Epub 2012 May 15.

PMID:
22589377
19.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

20.

Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.

Bruijnen ST, van der Weijden MA, Klein JP, Hoekstra OS, Boellaard R, van Denderen JC, Dijkmans BA, Voskuyl AE, van der Horst-Bruinsma IE, van der Laken CJ.

Arthritis Res Ther. 2012 Apr 2;14(2):R71. doi: 10.1186/ar3792.

Supplemental Content

Loading ...
Support Center